证券代码：002675 证券简称：东诚药业 公告编号：2025-078 二、董事会会议审议情况 全体董事经过审议，以现场结合通讯方式审议通过了《关于以集中竞价方式 回购股份方案的议案》。 内容详见公司刊载于《证券时报》、《证券日报》、《中国证券报》、《上 海证券报》和巨潮资讯网（www.cninfo.com.cn）《关于以集中竞价方式回购股 份方案的公告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 烟台东诚药业集团股份有限公司 第六届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025年12月31日，烟台东诚药业集团股份有限公司（以下简称"公司"）在 山东省烟台经济技术开发区长白山路7号公司会议室召开了第六届董事会第十七 次会议。会议通知于2025年12月28日以通讯方式送达。会议采用现场结合通讯方 式召开，会议应到董事9人，实到董事9人。公司全体高级管理人员列席了本次会 议。会议由公司董事长由守谊先生主持，会议召开符合《中华人民共和国公司法》 （以下简称"《公司法》"）及《烟台东诚药业集团 ...

Core Viewpoint - The company is making steady progress on its key products before the IPO, with specific timelines for NDA submissions for its investigational drugs [2] Group 1: Product Development Progress - The impurity supplement study for 18F-APN-1607 is ongoing, with no specific completion date mentioned [2] - The NDA for fluorine-18 labeled somatostatin analog (氟[18F]思睿肽) is expected to be submitted in the first half of 2026, while the NDA for fluorine-18 labeled alpha peptide (氟[18F]阿法肽) is anticipated in 2027 [2] - The pre-NDA communication for 99mTc-GSA is in progress, although specific details were not provided [2] Group 2: Market Strategy - The company is committed to actively promoting the research and development progress to expedite the market launch of its products [2]

Group 1 - The core point of the article is that Dongcheng Pharmaceutical has not yet disclosed sales data for its Sodium Fluoride Injection since its approval in May 2025, and future disclosures will be made in regular reports as required by regulations [1][2]. Group 2 - Investors inquired about the sales data, including volume, revenue contribution, and main sales regions/channels for the Sodium Fluoride Injection [1]. - Dongcheng Pharmaceutical confirmed that there is currently no available sales data for the product [1]. - The company advised investors to pay attention to future regular reports and announcements for updates on the product's operational status [1].

Group 1 - Dongcheng Pharmaceutical's stock price decreased by 1.03% to 13.49 yuan per share, with a total market capitalization of 11.12 billion yuan as of the report date [1] - The company, established on December 31, 1998, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate, with revenue composition as follows: 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - Xinyi Fund holds a significant position in Dongcheng Pharmaceutical, with its fund "Xinyi Healthcare A" owning 1.2349 million shares, representing 4.65% of the fund's net value, making it the sixth-largest holding [2] - The fund has a total scale of 261 million yuan and has achieved a year-to-date return of 22.12%, ranking 4110 out of 8087 in its category [2] Group 3 - The fund manager of Xinyi Healthcare A is Chen Xu, who has been in the position for nearly 5 years, with the fund's total assets amounting to 404 million yuan [3] - During Chen Xu's tenure, the best fund return was -20.35%, while the worst return was -22.24% [3]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The number of innovative drugs listed in China continues to grow, with domestic products accounting for approximately half of the total market share. The R&D capabilities for innovative drugs in China are also increasing, attracting global attention. Notably, the number and value of domestic innovative drug business development (BD) transactions have reached new highs, with ADC, bispecific antibodies, small nucleic acids, and CAR-T being the four key R&D directions to watch in 2026 [15][21][22] - The Chinese innovative drug market has seen a significant increase in the number of new drug applications (NDA), with domestic products making up a growing proportion. From 2017 to 2024, the number of innovative drugs listed in China rose from 41 to 92, with domestic products accounting for 50% of the total by 2024 [17][21] - The report highlights that the license-out transaction volume and total amount for Chinese companies reached $92.03 billion in the first three quarters of 2025, a 77% increase compared to the total for 2024. The upfront payment for license-out transactions has also surpassed the total financing amount in the primary market for the same period [22][25] Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a year-to-date increase of 14.29%, while the Hang Seng Healthcare Index has surged by 62.29% [3][8] - The report notes that the pharmaceutical sector has experienced fluctuations, with raw materials and medical devices showing positive growth [8] R&D Progress and Company Dynamics - The report provides an overview of the R&D progress for innovative and modified drugs, including approvals and clinical applications [5] - It lists key companies to watch in various sub-sectors, including innovative drugs, research services, and medical devices, with specific recommendations for companies like Innovent Biologics, Hengrui Medicine, and WuXi AppTec [11][12] Market Insights and Regulatory Observations - The report tracks the price-to-earnings ratio of the pharmaceutical index, noting that it is currently lower than historical averages [5] - It emphasizes the importance of the regulatory environment and market dynamics in shaping the future of the pharmaceutical industry [5]

Core Viewpoint - Dongcheng Pharmaceutical's stock price has been declining, causing concern among investors despite recent advancements in nuclear medicine research, product approvals, and inclusion in medical insurance [1] Group 1: Company Response - The company acknowledges that stock price fluctuations are influenced by various factors including macroeconomic conditions, market sentiment, and industry changes [1] - Dongcheng Pharmaceutical commits to fulfilling its information disclosure obligations and enhancing communication with investors [1] - The company emphasizes its strategy of high-quality development, aiming to improve operational efficiency and profitability to strengthen its core competitiveness and achieve long-term value growth [1]

Group 1 - The company Dongcheng Pharmaceutical (002675.SZ) clarified on the investor interaction platform that it has no relevant cooperation with TAE Technologies and its affiliates [1]

Group 1 - The company is a shareholder in Zhongborun Kang Medical and is responsible for the pharmaceutical research related to its BNCT drug BPA [1] - There is no collaboration between the company and TAE Life Sciences, a subsidiary of TAE Technologies in the United States [1]

Core Viewpoint - The company is actively preparing for the NDA submission of Fluorine-18 labeled Somatostatin Injection, with an expected submission in the first half of 2026, although the approval timeline remains uncertain [1] Group 1 - The company is currently working on the NDA submission preparations for the Fluorine-18 Somatostatin Injection [1] - The expected timeline for NDA submission is the first half of 2026 [1] - The approval timeline is uncertain and will depend on regulatory requirements [1]

Core Viewpoint - Dongcheng Pharmaceutical aims to strengthen its core business, enhance public opinion monitoring, optimize development quality, and improve long-term investment value [2] Group 1 - The company is committed to solidifying its main business operations [2] - The company plans to focus on public opinion monitoring to better manage its reputation [2] - The company is working towards optimizing its development quality to enhance overall performance [2] - The company is dedicated to increasing its long-term investment value for stakeholders [2]